Shao Jian-Yong
    Title Professor and Director

    Jian-Yong Shao, MD/PhD, is the professor of oncology and director of Department of Molecular Diagnostics at Sun Yat-sen University Cancer Center (SYSUCC). He also served as the director of Tumor Gene Diagnostic Center in South China and the vice-director of pathology department at SYSUCC. He specializes in molecular and pathologic diagnosis of various cancers, and also works on promoting theuse of advanced molecular diagnostic techniques into the diagnosis and targeted therapy of tumors in clinical practice. Besides his clinical activities, he is appointed as vice-chairman of Chemotherapy Anti-Cancer Association in Guangzhou China, committee member of Molecular Pathology Quality Control Center, committee member of Lung Cancer Diagnosis and Treatment Quality Control Center of Ministry of Health in China, and committee member of Chinese Anti-Cancer Association.

    He has been editorial board member of Cancer Biology, AmericanJournal of Translational Research, ISRN Pathology, Chinese Journal of Cancer, World Journal of Oncology, and World Journal of Clinical Oncology. He successively presides over or is mainly responsible for two projects of National Major Fundamental Research Program of China (973 and 863 programs) and15 projects of Natural Science Foundation of China or Science Project of Guangdong Province, in addition to which he joins in 15 other research projects in China. He has authored or co-authored over 110 papers in authoritative magazines.

    He has achieved first prize of Science and Technology in Guangdongin 2010 for involving in completing research of “Study of foundation and of key technique of gene therapy in cancer”, and first prize of Nomination of National NaturalScience of Ministry of Education in 2002, first prize of Chinese MedicalScience and Technology Award in 2004, and second class prize of NationalNatural Science in China in 2005 for involving in completing research of “Molecular Genetics of Nasopharyngeal carcinoma”.

    Research Interest(s)
    The mainscientific interests of Prof. Shao JY are the development of molecularclassification and molecular target therapy of cancer, including usingmolecular biological methods to identify new molecular signature for variouscancers, establishing molecular marker-based risk prediction model for cancertreatment, and bringing basic scientific discoveries into clinical practice.

    For information on Professor Shao's laboratory, click here and select: Translation of novel genetic biomarkers of various malignancies into clinical practice.


    2000.07-2012.04:Received a Ph.D at KarolinskaInstitutet in Sweden

    2000.07-2002.12:Received a Ph.D at SunYat-sen University Cancer Center in Guangdong, China

    1999.10-2000.11:Engaged advanced studies ononcological molecular biology at Karolinska Institutet in Sweden

    1997.01-1997.07:Engaged advanced studies onmolecular pathology at Chinese University of Hong kong

    1989.09-1992.07:Received a Master degree at SunYat-sen University in Guangdong, China

    1984.09-1989.07:Received a Bachelor degree at Bengbu MedicalCollege in Anhui, China

    1.        WangHY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, Zeng YX, Shao JY*. Profiling PlasmaMicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing. Clin Chem. 2014 60:773-782 (IF=7.149)

    2.        FuS, Wang F, Shao Q, Zhang X, Duan LP, Zhang X, Zhang L, Shao JY*.Detection ofEML4-ALK Fusion Gene in Chinese Non-Small Cell Lung Cancer by Using a SensitiveQuantitative Real-Time Reverse Transcriptase PCR Techniqu. Diagn Mol Pathol.2014 Jan 30.(IF=1.861)

    3.        ZhangZC, Li YY, Wang HY, Fu S, Wang XP, Zeng MS, Zeng YX, Shao JY*.Knockdown ofmiR-214 Promotes Apoptosis and Inhibits Cell Proliferation in NasopharyngealCarcinoma. PLoS One. 2014 21;9(1):e86149. (IF=3.73)

    4.        JiaSW, Fu S, Wang F, Shao Q, Huang HB, Shao JY*. ALK gene copy number gain and itsclinical significance in hepatocellular carcinoma. World J Gastroenterol. 2014Jan 7;20(1):183-92. (IF=2.547)

    5.        ZhaoZR. Wang JF. Lin YB. Wang F. Fu S. Zhang SL. Su XD. Jiang L. Zhang YG. ShaoJY*. Long H..Mutation abundance affects the efficacy of EGFR tyrosine kinaseinhibitor readministration in non-small-cell lung cancer with acquiredresistance. Med Oncol. 2014 Jan;31(1):810. (IF=2.147)

    6.        LiYY, Fu S, Wang XP, Wang HY, Zeng MS, Shao JY*. Down-regulation of c9orf86 inhuman breast cancer cells inhibits cell proliferation, invasion and tumorgrowth and correlates with survival of breast cancer patients. PLoS One. 2013Aug 14;8(8):e71764. (IF=3.73)

    7.        WangF, Fu S, Shao Q, Zhou YB, Zhang X, Zhang X, Xue C, Lin JG, Huang LX, Zhang L,Zhang WM, and Shao JY*. High EGFR copy number predicts benefits from tyrosinekinase inhibitor treatment for non-small cell lung cancer patients withwild-type EGFR. J Transl Med. 2013; 11: 90. (IF= 3.459)

    8.        ZhangJX, Cai MB, Wang XP, Duan LP, Shao Q, Tong ZT, Liao DZ, Li YY, Huang MY, ZengYX, Shao JY*. Elevated DLL4 expression is correlated with VEGF and predictspoor prognosis of nasopharyngeal carcinoma. Med Oncol. 2013 Mar;30(1):390. (IF=2.147)

    9.        HuC, Wei W, Chen X, Woodman CB, Yao Y, Nicholls JM, Joab I, Sihota SK, Shao JY,Derkaoui KD, Amari A, Maloney SL, Bell AI, Murray PG, Dawson CW, YoungLS,Arrand JR. A global view of the oncogenic landscape in nasopharyngealcarcinoma: an integrated analysis at the genetic and expression levels. PLoSOne. 2012;7(7):e41055. (IF= 3.73)

    10.    CaiMB, Han HQ, Bei JX, Liu CC, Lei JJ, Cui Q, Feng QS, Wang HY, Zhang JX, Liang Y,Chen LZ, Kang TB, Shao JY, Zeng YX. Expression of human leukocyte antigen G isassociated with prognosis in nasopharyngeal carcinoma. Int J Biol Sci.2012;8(6):891-900. (IF= 3.168)

    11.    LiXJ, Peng LX, Shao JY, Lu WH, Zhang JX, Chen S, Chen ZY, Xiang YQ, Bao YN, ZhengFJ, Zeng MS, Kang TB, Zeng YX, Teh BT, Qian CN. As an independent unfavorableprognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma throughinduction of epithelial-mesenchymal transition and activation of AKT signaling.Carcinogenesis. 2012 Jul;33(7):1302-9. (IF= 5.635)

    12.    CaiMB, Wang XP, Zhang JX, Han HQ, Liu CC, Bei JX, Peng RJ, Liang Y, Feng QS,WangHY, Chen LZ, Fu S, Kang T, Shao JY, Zeng YX. Expression of heat shock protein70 in nasopharyngeal carcinomas: different expression patterns correlate withdistinct clinical prognosis. J Transl Med. 2012 May 16;10:96. (IF= 3.459)

    13.    WangHY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, Zeng YX, Shao JY*. Secreted proteinacidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinomametastasis and poor prognosis. J Transl Med. 2012;10(1):27. (IF= 3.459)

    14.    DuZM, Kou CW, Hu CF, Chen J, Wang HY, Yan LX, Ernberg I, Zeng YX, and Shao JY*.Clinical Significance of Elevated Spleen Tyrosine Kinase Expression inNasopharyngeal Carcinoma. Head and Neck,2012. doi: 10.1002/hed.21953. (IF= 2.833)

    15.    ZhangLJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH. Relationshipbetween epidermal growth factor receptor gene mutation and copy number inChinese patients with non-small cell lung cancer. Chin J Cancer. 2012. Hai-YunWang, Bing-Yu Sun, Zhi-Hua Zhu, Ellen T. Chang, Ka-Fai To, Jacqueline S.G.Hwang, Hao Jiang,Michael Koon-Ming Kam, Gang Chen, Shie-Lee Cheah, Ming Lee,Zhi-Wei Liu, Jing Chen, Jia-Xing Zhang,Hui-Zhong Zhang, Jie-Hua He, Fa-LongChen, Xiao-Dong Zhu, Ma-Yan Huang, Ding-Zhun Liao, Jia Fu,Qiong Shao, Man-BoCai, Zi-Ming Du, Li-Xu Yan, Chun-Fang Hu, Ho-Keung Ng, Joseph T.S. Wee,Chao-NanQian, Qing Liu, Ingemar Ernberg, Weimin Ye, Hans-Olov Adami, Anthony T. Chan,Yi-Xin Zeng,and Shao JY*. An Eight-signature Classifier for Prediction ofNasopharnyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011; 29(34):4516-4525. (IF=18.083)

    16.    DuZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY*, Ernberg I. Upregulation ofMiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMP1 and LMP2A andDownregulates a Negative Prognostic Marker JMJD1A. PLoS One. 2011; 6(4):e19137.(IF= 3.73)

    17.    ZhangY, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS,Huang W, Zeng YX, Shao JY*. miR-125b is Methylated and Functions as A TumorSuppressor by Regulating the ETS1 proto-oncogene in Human Invasive Breast Cancer.Cancer Res. 2011;71(10):3552-62. (IF= 8.65)

    18.    LiXJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WQ, Zhang ZF, PetilloD, Lin Q, Bao YN, Zheng FJ, Claramae SC, N Gopalakrishna lyer, Kang BT, ZengYX, Khee CS, Jeffrey MT, Teh BT, Qian CN. Serglycin Is a Theranostic Target inNasopharyngeal Carcinoma that Promotes Metastasis. Cancer Res.2011;71(8):3162-3172. (IF= 8.65)

    19.    AnX, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH. PlasmaEpstein-Barr virus DNA level strongly predicts survival in metastatic/recurrentnasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011;117(16):       3750-7. (IF= 5.201)

    20.    YanLX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, ZengYX, Shao JY*. Knockdown of miR-21 in human breast cancer cell lines inhibitsproliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res.2011;13(1):R2. (IF= 5.872)

    21.    LiYH, Wang F, Shen L, Deng YM, Shao Q, Feng F, An X, Wang FH, Wang ZQ, Xu RH,Shao JY*. EGFR FISH Pattern of Chromosome 7 Disomy Predicts Resistance toCetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. Clin. CancerRes. 2011;17(2):382-90. (IF= 7.837)

    22.    ShaoJY*, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, Liang XM, Hu LF, Ingemar E, LinDX, Zeng YX. A single nucleotide polymorphism in the Matrix Metalloproteinase-2promoter is closely associated with high risk of nasopharyngeal carcinoma inCantonese from southern China. Chin. J. Cancer, 2011;30(9):620-6. (IF= 0.448)

    23.    CaoY, Miao XP, Zeng YX, Lin DX, Shao JY*. Association between geneticpolymorphisms of CYP2A13, CYP2A6 and risk of nasopharyngeal carcinoma insouthern Chinese population. Cancer Biology, 2011;1(1). (IF= 3.287)

    24.    ZhangY, Hu CF, Chen J, Yan LX, Zeng YX, Shao JY*. LATS2 is de-methylated and overexpressedin nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer.2010;10:538. (IF= 3.333)

    25.    CaoY, Miao XP, Huang MY, Deng L, Lin DX, Zeng YX, Shao JY*. Polymorphisms of deathpathway genes FAS and FASL and risk of nasopharyngeal carcinoma. Mol. Carcinog.2010;49(11):944-50. (IF= 4.269)

    26.    CaoY, Miao XP, Huang MY, Deng L, Liang XM, Lin DX, Zeng YX, Shao JY*.Polymorphisms of methylenetetrahydrofolate reductase are associated with a highrisk of nasopharyngeal carcinoma in a smoking population from southern China.Mol. Carcinog. 2010;49(11):928-34. (IF= 4.269)

    27.    KongQL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ,Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, ZengMS.Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymaltransition and increases the number of side population stem-like cancer cellsin nasopharyngeal carcinoma. PLoS Pathog. 2010; 6(6):e1000940. (IF= 8.136)

    28.    ValentineR, Dawson CW, Hu C, Shah KM, Owen TJ, Date KL, Maia SP, Shao J, Arrand JR,Young LS, O'Neil JD. Epstein-Barr virus-encoded EBNA1 inhibits the canonicalNF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. MolCancer. 2010;9:1. (IF= 5.134)

    29.    GuoBH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS. Lowexpression of Mel-18 predicts poor prognosis in patients with breast cancer.Ann Oncol. 2010;21(12):2361-9. (IF= 7.384)

    30.    ChenJ, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX and Shao JY*. Epstein-BarrVirus Encoded Latent Membrane Protein 1 Regulates mTOR Signaling Pathway GenesWhich Predict Poor Prognosis of Nasopharyngeal Carcinoma. J. Transl. Med.2010;8:30. (IF= 3.459)

    31.    DuZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, Zeng YX, Shao JY*. Upregulation ofcaveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cellmigration and correlated with poor prognosis of the patients. Int. J. Cancer.2009; 125(8):1832-41. (IF= 6.198)

    32.    YanLX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY*. MicroRNAmiR-21 Overexpression in Human Breast Cancer is Associated with AdvancedClinical Stage, Lymph Node Metastasis and Patient Poor Prognosis. RNA. 2008 14:2348-2360. (IF= 5.088)

    33.    PangLJ, Shao JY*, Liang XM, Xia YF, Zeng YX. Mitochondrial DNA somatic mutationsare frequent in nasopharyngeal carcinoma. Cancer Biol. Ther. 2008,7(2):198-207. (IF= 3.287)

    34.    LiYH, Hu CF, Shao Q, Huang MY, Hou JH, Xie D, Zeng YX, Shao JY*. ElevatedExpressions of Survivin and VEGF Protein Are Strong Independent Predictors ofSurvival in Advanced Nasopharyngeal Carcinoma. J Transl Med. 2008, 3;6(1):1.(IF= 3.459)

    35.    ZhuZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD, Wu QL, LingP, Chen M, Xie ZM, Hu Y, Rong TH. Three immunomarker support vectormachines-based prognostic classifiers for stage IB non-small-cell lung cancer.J Clin Oncol. 2009; 27(7): 1091-9. (IF= 18.038)

    36.    CheungAK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, LiuET, Shao JY, Kou CW, Chua D, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML.Functional analysis of a cell cycle-associated, tumor-suppressive gene, proteintyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res.2008;68(19):8137-45. (IF= 8.65)

    37.    CaoY, Miao XP, Huang MY, Deng L, Hu LF, Ernberg I, Zeng YX, Lin DX, Shao JY*.Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in theCantonese population. BMC Cancer, 2006, 6:167. (IF= 3.333)

    38.    LiY, Shao JY, Liu RY, Zhou L, Chai LP, Li HL, Han HY, Huang BJ, Zeng MS, Zhu XF,Liu Q, Fu LW, Huang WEvaluation of Long-Term Toxicity of Ad/hIFN-gamma, anAdenoviral Vector Encoding the Human Interferon-gamma Gene, in NonhumanPrimates. Hum Gene Ther. 2008;19(8):827-39. (IF= 4.019)

    39.    LiuMZ, Xie D, Mai SJ, Tong ZT, Shao JY, Fu YS, Xia WJ, Kung HF, Guan XY, Zeng YX.Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely withadvanced tumor stage. Am J Clin Pathol. 2008;129(5):728-34. (IF= 2.881)

    40.    LiHL , Li S , Shao JY , Lin XB , Cao Y , Jiang WQ , Liu RY , Zhao P , Zhu XF ,Zeng MS , Guan ZZ , Huang W. Pharmacokinetic and pharmacodynamic study ofintratumoral injection of an adenovirus encoding endostatin in patients withadvanced tumors. Gene Ther. 2008;15(4):247-56. (IF= 4.321)

    41.   Song LB; Zeng MS; Liao WT, Zhang Ling, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF,Fu LW, HuangWL, Goberdhan PD, Vimia B, Zeng YX. Bmi-1 is a novel molecularmarker of nasopharyngeal carcinoma progression and immortalizes primary humannasopharyngeal epithelial cells. Cancer Res. 2006;6(12):6225-32. (IF= 8.65)

    42.    PanZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, Jiang JH, Guo C, Eugene Z, IngemarE, Zeng YX. High frequency somatic mutations in RASSF1A in nasopharyngealcarcinoma. Cancer Biol Ther. 2005;4(10):1116-22. (IF= 3.287)

    43.   PanZZ, Wan DS, Zhang CQ, Shao JY, Li LR, Chen G, Zhou ZW, Wang FL. Usingp53-immunostained large specimens to determine the distal intramural spreadmargin of rectal cancer. World J Gastroenterology,2006;12(10):1626-9. (IF= 2.547)

    44.    Shao JY, Li YH, Zhang Y, et al. Comparison of Plasma Epstein-Barr Viruses DNALevel and Serum EBV VCA/IgA Antibody Titers in Nasopharyngeal Carcinoma.Cancer, 2004, 100: 1162-1170. (IF= 5.201)

    45.   ShaoJY, Ernberg I, Biberfeld, et al. Immunostaining studies on nasopharyngealcarcinoma: Interaction of tumor cells, lymphocytes and expression of EBV LMP1.Anticancer Research, 2004, 24(4):2309-2318. (IF= 1.872)

    46.   ShaoJY, Gao HY, Li YH, Zhang Y, Lu YY, Zeng YX. Quantitative detection of commondeletion of mitochondrial DNA in hepatocellular carcinoma and hepatocellularnodular hyperplasia. World J Gastroenterol. 2004;10(11):1560-4. (IF= 2.547)

    47.   ShaoJY, Gao HY, Li YH, et al. High frequency of common deletion (4981 bp) inmitochondrial DNA in nasopharyngeal carcinoma and its correlation with patientage and clinical stages. Cancer Biology & Therapy, 2004, 3(12):1270-1274.(IF= 3.287)

    48.    Shao JY, Zhang Y, Li YH, et al. Comparison of Epstein-Barr virus DNA level inplasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma:correlations with clinical parameters. Anticancer Research, 2004,24(6):4059-4066. (IF= 1.713)

    49.   Shao JY, Li YH, Wu QL, et al. High frequency loss of heterozygosity on thelong arm of chromosome 13 and 14 in nasopharyngeal carcinoma in Southern China.Chinese Medical Journal, 2002, 115(4):571-575. (IF= 0.901)

    50.   Shao JY, Huang XM, Yu XJ, et al. Loss of Heterozygosity and its correlation withclinical outcome and Epstein-Barr Virus Infection in Nasopharyngeal Carcinoma.Anticancer Research, 2001, 21(4): 3021-3030. (IF= 1.713)

    51.   Shao JY, Wang HY, Huang XM, et al. Genome-wide allelotype analysis of sporadicprimary nasopharyngeal carcinoma from southern China. Int. J Oncology, 2000,17: 1267-1275. (IF= 2.657)

    52.   XiaomingH, Haiqiang M, Manquan D, Jianyong S, Yong S, Kela L, Xiaoman L, Tengbo H.Examination of nasopharyngeal epithelium with contact endoscopy. ActaOtolaryngol, 2001: 121: 95-102. (IF= 1.106)

    53.   GuoX, Min HQ, Zeng MS, Qian CN, Huang XM, Shao JY, Hou JH. nm23-H1 expression innasopharyngeal carcinoma: correlation with clinical outcomes. Int. J. Cancer,79(6):596-600, 1998. (IF= 5.007)

    54.   王小拍,吴兴平,颜黎栩,邵建永*.血清miR-103可作为乳腺癌潜在的诊断标记物.南方医科大学学报,2012,32(5):631-634.

    55.   李喆,张兰军,王武平,郭康,邵建永,戎铁华.非小细胞肺癌组织中表皮生长因子受体基因突变与拷贝数之间的相关性以及与患者临床病理特征之间的关系.中华肿瘤学杂志,2011,33(9):666-670.

    56.   王芳,付莎,汤涛,邓玲,张晓,李银珍,邵建永*.非小细胞肺癌表皮生长因子受体基因突变与临床病理特征的关系.中华病理学杂志,2011,40(10):664-666.

    57.   赛克,王芳,牟永告,张湘衡,柯超,邵建永等.胶质瘤1p/19q联合缺失特征分析.中国神经精神疾病,2011,37(8):490-494.

    58.    寇昌伟,胡春芳,邵琼,邵建永*.鼻咽癌中脾酪氨酸激酶高表达和启动子甲基化意义.中国肿瘤,2010,19(1):63-66

    59.   吴其年,黄马燕,吴秋良,邵建永,宗永生等.DLL4表达水平与浸润性导管癌术后生存率的关系.广东医学,2010,31(11):1441-1443.

    60.   黄秀芳,颜黎栩,李晓霞,杜紫明,邓玲,梁小曼,邵建永*.乳腺癌差异表达的MicroRNA的筛选研究.中山大学学报(医学科学版),2009,30(1):69-73;77.

    61.   颜黎栩,黄马燕,吴秋良,邵建永*.miR-21表达异常与乳腺癌临床病理特征及预后的关系.中国病理生理杂志,2009,25(4):676-681.

    62.    曾益新,邵建永.肿瘤的分子分型与分子靶向治疗.中国医药生物技术,2008,3(1):6-7.

    63.   李晓霞,李瑞平,杜紫明,曾木圣,邵建永*.鼻咽癌差异表达miRNAs筛选研究.中山大学学报(医学科学版),2007,28(6):607-612.

    64.   李瑞平,邵建永,邓玲,曾木圣,宋立兵,李满枝,吴秋良.利用原代细胞培养和人全基因表达谱芯片筛选鼻咽癌差异表达基因.南方医科大学学报,2007,28(7):1156-1160.

    65.   侯雪,张力,赵充,李苏,卢丽霞,韩非,邵建永,黄培钰.血浆EB病毒DNA浓度预测鼻咽癌远处转移的研究.癌症,2006,25(7):785-792.

    66.   祝曙光,张惠忠,熊利华,廖洪映,邵建永.微血管密度在非小细胞肺癌中的预后意义.中山大学学报(医学科学版),2006,27(3S):39-41.

    67.    胡春芳,邵琼,侯景辉,邵建永*.VEGF在鼻咽癌组织芯片中的表达与预后的关系.中国肿瘤杂志,2006,15(7):466-469.

    68.    彭娟,丁童,郑利民,邵建永*.肿瘤相关巨噬细胞对NPC进展和预后的影响.癌症,2006,25(11):1340-1345

    69.   张海芳,邓玲,黄马燕,邵建永*.荧光实时定量PCR检测肺癌组织表皮生长因子受体基因突变的临床应用价值.新医学,2006,37(9):581-584.

    70.    黄马燕,邓玲,王芳,邵建永.MMP-9基因多态性与鼻咽癌遗传易感性的关系研究.中国病理生理杂志,2007,5(35):335-342.

    71.    陈艳,邵建永,吴秋良.肿瘤患者血浆DNA变异检测及其临床意义.国外医学肿瘤学分册,2005,32(5):358-361.

    72.    顾霞,林汉良,邵建永,张萌,朱有凯,梁惠珍,马怡晖.转染survivin反义mRNA对Jurkat淋巴瘤细胞生长和化疗敏感性的影响.中华病理学杂志,2005,34(11):737-741.

    73.    陈艳,吴秋良,邵建永*.线粒体细胞色素氧化酶RNAi慢病毒载体的构建.中国病理生理杂志,2005,21(6):1117-1123

    74.    庞玲娟,梁小曼,邵建永*.电离辐射与线粒体DNA的变异.广东医学院学报,2005,23(2):217-220.

    75.    庞玲娟,梁小曼,邵建永*.鼻咽癌组织线粒体DNA突变的研究.中国肿瘤,2005,14(5):30-34.

    76.   张玉,郜红艺,冯惠霞,邵建永.鼻咽癌病人血浆和外周血细胞EB病毒DNA定量分析.中华医学杂志,2004,84(12):982-986.

    77.   李宇红,邵建永,郜红艺,等.鼻咽癌病人游离血浆EBV/DNA定量检测及其临床意义.中国肿瘤临床,2004,31(8):421-424.

    78.    李宇红,邵建永,李苏,邹本燕,等.鼻咽癌患者血清VEGF、CD44s、MMP-3蛋白定量检测及其临床意义.癌症,2004,23(9):1060-1064.

    79.   李宇红,邵建永,姜文奇.鼻咽癌组织中MMP-9、CD44v6蛋白表达的检测及其临床意义.中国肿瘤临床,2004,31(20):1155-1158.

    80.    吴晶晶,邵建永,吴秋良.线粒体DNA突变与肿瘤的关系(综述),中华中西医杂志,2003,4(24):3261-3265.

    81.    李宇红,邵建永,赵美卿,等.EBV DNA定量分析在监测鼻咽癌转移和复发中的临床意义.癌症,2003,22(6):645-648.

    82.   陈少华,邱前辉,邵建永.EBV潜伏膜蛋白-1表达与鼻咽癌增殖和凋亡关系的研究.耳鼻咽喉-头颈外科学,2003,10(3):168-172.

    83.    周虹,邵建永,吴秋良.左枕部皮肤表皮囊肿原位癌变1例.诊断病理学杂志,2003,10(2):106.

    84.    程钢,邵建永,陈志等.鼻咽癌外周血免疫指标研究.第一军医大学学报,2002,22(12):1104-1105.

    85.   何洁华,梁小曼,吴秋良,饶慧兰,林素瑕,张惠中,邵建永.乳腺穿刺细胞学诊断报告方式的探讨——1999年761例次乳腺穿刺细胞学诊断分析.江西医学杂志,2002,20(4):209-212.

    86.    邵建永,曾微芬,曾益新.鼻咽癌分子遗传学研究进展.癌症,2002,21(1):1-10.

    87.   饶慧兰,侯景辉,黄奕莉,郝亚萍,张惠中,邵建永,林汉良.涎腺恶性淋巴上皮病变临床病理特征及其与EB病毒的相关性.癌症,2001,20(3):270-273.

    88.    邵建永,王辉云,黄晓明等.鼻咽癌全基因组杂合性缺失分析.癌症,2001,20(12):1225-1232.

    89.   邵建永,李晓明,刘宗石,林汉良.原发性肝癌患者17号和16号染色体等位基因杂合性丢失的研究.中华医学杂志,1999,79(6):428-430.

    90.   邵建永,李晓明,刘宗石,吴秋良,梁小曼,侯景辉等.原发性肝细胞癌1号染色体杂合子丢失的初步研究.中华病理学杂志,1999,28(1):28-30.

    91.   邵建永,Liew Choong-Tsek,李晓明,吴秋良等.原发性肝癌9号染色体等位基因杂合性丢失研究.癌症,1999,18(1):16-19.

    92.   邵建永,刘宗石,李晓明,梁小曼,吴秋良等.人原发性肝癌10号染色体等位基因杂合性丢失.中国肿瘤临床,1999,26(6):51-54.

    93.   邵建永,李晓明,侯景辉,刘宗石等.原发性肝细胞癌多染色体杂合性丢失研究.癌症,1999,18(5):520-524

    94.   侯景辉,邵建永,饶慧兰,吴秋良.微卫星多态性分析技术检测肿瘤组织等位基因杂合性缺失在石蜡标本上的应用.中华病理学杂志,1999,28(6):463-464.

    95.   潘志忠,万德森,张昌卿,冯海涛,邵建永等.大肠癌组织p53,PCNA表达与临床病理及预后的关系.癌症,1999,18(5):586-587.

    96.   王辉云,关新元,方燕,元云飞,梁启万,夏建川,邵建永,李辉梅.肝癌染色体DNA拷贝数的变化及其与临床病理和预后的关系.癌症,1999,18(5):509-513.

    97.    邵建永,侯景辉,吴秋良等.幽门螺杆菌与胃、肠淋巴瘤关系的免疫组化初步研究.癌症,1998,17(5):383-384.

    98.    潘志忠,万德森,张昌卿,冯海涛,邵建永等.结肠癌根治术COX模型预后分析.广东医学,1998,19(11):822-823.

    99.    潘志忠,万德森,张昌卿,冯海涛,邵建永等.影响结肠癌根治术预后的多因素分析.中华肿瘤杂志,1998,21(1):68.









    108. 邵建永,周慕珩,叶玉玲等.用原位杂交和免疫组化技术检测人阴茎癌和阴茎尖锐湿疣组织中人乳头状瘤病毒.中国癌症研究进展,1993,(1):169-173.

    109. 吴惠茜,邵建永,林汉良.介绍一种不加盖玻片的核酸原位杂交改良法.中山医科大学学报,1993,14(2):156-158.

    Updated by International Office, Sun Yat-sen University Cancer Center

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.